ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Treatment Nasdaq: ZIOP
ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Treatment – Very first Patient Treated with Non-viral Sleeping Beauty Modified CAR-T Cells Produced in two Weeks – Anticipate Phase...
